ARGX ARGENX SE
Company Analysis
Latest News
Argenx beats Q3 2026 expectations with $1.72B in Vyvgart sales, up 54% year-over-year
argenx SE reported third quarter 2026 product net sales of $1.72 billion, exceeding analyst expectations of $1.63 billion and representing 54% year-over-year...
🔴 argenx is trading 4.6% down in pre-market after Q3 results and higher expense outlook
argenx is trading 4.59% down at $849.19 ahead of its October 22, 2026 earnings call. The Q3 release is the clearest company-specific event preceding the move,...
argenx NV Q3 2026 Earnings Preview: What Analysts Expect on October 22, 2026
Analysts expect argenx to report Q3 2026 revenue of $1.63 billion and EPS of $7.44, with the stock trading around $869.72 against a consensus target of...
🟢 argenx is trading 4.23% up on October 20, 2026, amid positive Phase 3 ALKIVIA data
argenx is trading at $860.54, up +4.23%, amid positive Phase 3 ALKIVIA data announced October 19. - The autoimmune myositis trial met its primary endpoint,...
🟢 argenx is trading 28.12% up in after-hours trading with no confirmed catalyst
argenx is trading at $1049.46, up 28.12% in after-hours, with the cause unconfirmed. - No verified October 16 company announcement or late-breaking catalyst...
🟢 argenx is trading 4.46% up
argenx is trading up 4.46% at $854.81 on October 15, with no clear company-specific catalyst identified for the intraday gain. - The company announced it will...
🔴 argenx is trading 4.3% down in after-hours trading with no confirmed catalyst
argenx is trading 4.25% lower at $790.00 after-hours, with no clear, confirmed catalyst identified. - The regular-session close was $825.03. - On October 8,...
🔴 argenx is trading 11% down today after Phase 3 Sjögren’s trial stopped for futility
argenx is trading 11.12% down at $825.17 after announcing it would discontinue its Phase 3 UNITY study of efgartigimod in adults with moderate-to-severe...
Argenx Loses a Big Bet on Sjogren's Disease — Can Its Blockbuster Drug Still Carry the Company?
Shares of argenx plunged 15.9% to $781.00 on October 8 after the company killed its late-stage trial for Sjögren's disease, erasing roughly $9 billion in...
🔴 argenx is trading 15.88% down in pre-market after UNITY deemed unlikely to meet primary endpoint
argenx is trading at $781.00 (-15.88%) in pre-market after its October 8 announcement that it would discontinue its Phase 3 UNITY study, which an independent...
Argenx presents VYVGART data supporting earlier, sustained treatment
Argenx announced new data on VYVGART for presentation at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and...
argenx NV Q2 2026 Earnings Preview: What Analysts Expect on July 23, 2026
argenx is expected to report consensus revenue of $1.45 billion and earnings per share of $6.27 for the second quarter of 2026, with the current stock price of...
argenx NV Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
Consensus estimates for argenx NV point to Q1 2026 revenue of $1.34 billion and earnings per share of $5.16, while the stock currently trades at $794.86...
argenx NV Reports Q4 2025 Earnings on February 26, 2026
argenx is expected to report Q4 2025 revenue of $1.29 billion and EPS of $6.20, with the current stock price of $840.28 trailing the average analyst target of...